|Company:||Mammography & Ultrasound Specialists|
|Subject:||Mammography Quality Standards|
|Issuer:||Dallas District Office|
|Issued:||Jan. 31, 2006||Closed:||
Department of Health and Human Services
Public Health Service
Southwest Regional Office
January 31, 2006
Via Federal Express - Next Day
Re: MQSA Inspection ID #204065
Chief Executive Officer
Mammography & Ultrasound Specialists
6611 S. Rice Avenue
Bellaire, TX 77401
Dear Ms. Burleson,
On January 10, 2006, a representative of the Food and Drug Administration (FDA) conducted an investigation at your facility which revealed a serious problem involving the conduct of mammography. Under the Mammography Quality Standards Act of 1992 ("MQSA") which is codified in Section 263b of Title 42 of the United States Code (USC), you must meet specific requirements to practice mammography. These requirements serve to protect the health of women by assuring that a facility can perform quality mammography.
The problem identified during this investigation constitutes a violation of the MQSA as identified below.
Failed to produce documents verifying that your facility was operating with a valid FDA MQSA certificate. Your current FDA MQSA certificate expired on October 31, 2005. Your facility has operated without a valid FDA MQSA certificate from November 1, 2005 through December 20, 2005. [See 21 CFR 900.11(a)].
Because this violation may be indicative of serious underlying problems that could compromise the quality of mammography at your facility, FDA may take additional actions including, but not limited to, the following:
You should respond in writing to FDA within fifteen (15) working days from the date you receive this letter. Your response should address the findings listed above and include:
1. The specific steps you have taken, or will take to correct all of the violations noted in this letter, including projected timeframes for implementing those steps;
2. The specific steps you have taken, or will take, to prevent the recurrence of similar violations, including projected timeframes for implementing those steps.
Please submit your response to this letter to:
Deborah M. McGee
Food and Drug Administration
4040 N. Central Expressway, Suite 900
Dallas, TX 75204
Finally, you should understand that there are many requirements pertaining to mammography. This letter pertains only to violations related to the recent investigation of your facility and does not necessarily address other obligations you have under the law. You may obtain general information about all of FDA's requirements for mammography facilities by contacting the Mammography Quality Assurance Program, Food and Drug Administration, P.O. Box 6057, Columbia, MD 21045-6057 (1-800-838- 7715) or through the Internet at http://www.fda.gov/cdrh/mammography/index.html .
If you have additional or more specific questions about mammography facility requirements, or about the content of this letter, please feel free to contact Deborah M. McGee, M.S., Southwest Regional Compliance Officer, by telephoning (214) 253-4935.
Dennis E. Baker
Regional Food and Drug Director
Southwest Regional Office
Texas Department of State Health Services
Regulatory Services, Environmental and
Consumer, Inspection Unit
1100 W. 49th Street
Austin, TX 78756-3189
Attn: Jerry Cogburn
Priscilla F. Butler, M.S., FAAPM
Director, Breast Imaging Accreditation Programs,
American College of Radiology
1891 Preston White Drive
Reston, Virginia 22091